Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study

Arianna Di Stadio; Evanthia Bernitsas; Domenico Antonio Restivo; Enrico Alfonsi; Rosario Marchese-Ragona

doi:10.1016/j.jvoice.2018.01.002

Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study

Arianna Di Stadio, Evanthia Bernitsas, Domenico Antonio Restivo, Enrico Alfonsi, Rosario Marchese-Ragona

Istituto di Neuroriabilitazione Motoria San Camillo

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVES: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation.

MATERIALS AND METHODS: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A.

RESULTS: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6-8 months.

CONCLUSIONS: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

Original language	English
Journal	Journal of Voice
DOIs	https://doi.org/10.1016/j.jvoice.2018.01.002
Publication status	E-pub ahead of print - Apr 9 2018

Access to Document

10.1016/j.jvoice.2018.01.002

Cite this

@article{0a32b1490b6b456aa46f38b80cefb688,

title = "Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study",

abstract = "OBJECTIVES: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation.MATERIALS AND METHODS: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A.RESULTS: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6-8 months.CONCLUSIONS: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.",

author = "{Di Stadio}, Arianna and Evanthia Bernitsas and Restivo, {Domenico Antonio} and Enrico Alfonsi and Rosario Marchese-Ragona",

year = "2018",

month = apr,

day = "9",

doi = "10.1016/j.jvoice.2018.01.002",

language = "English",

journal = "Journal of Voice",

issn = "0892-1997",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A

T2 - A Pilot Study

AU - Di Stadio, Arianna

AU - Bernitsas, Evanthia

AU - Restivo, Domenico Antonio

AU - Alfonsi, Enrico

AU - Marchese-Ragona, Rosario

PY - 2018/4/9

Y1 - 2018/4/9

N2 - OBJECTIVES: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation.MATERIALS AND METHODS: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A.RESULTS: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6-8 months.CONCLUSIONS: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

AB - OBJECTIVES: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation.MATERIALS AND METHODS: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A.RESULTS: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6-8 months.CONCLUSIONS: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

U2 - 10.1016/j.jvoice.2018.01.002

DO - 10.1016/j.jvoice.2018.01.002

M3 - Article

C2 - 29650331

JO - Journal of Voice

JF - Journal of Voice

SN - 0892-1997

ER -

Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study

Abstract

Access to Document

Fingerprint

Cite this